NextCure NXTC
NASDAQ NXTC
$6.40 +0.17 (+2.73%)
At close: Nov 13, 2026 · 4:00 PM EST

NextCure (NXTC) EBITDA Margin (2019 - 2020)

Updated

NextCure (NXTC) posted EBITDA Margin of -168.97% for FY2020, up 379.04 percentage points from -548.01% in FY2019.

Analysis

NextCure (NXTC) EBITDA Margin (2019 - 2020) Analysis & Trends

  • Business Quant data shows NXTC's EBITDA Margin at -548.01% in FY2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn 36.69%
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn 32.68%
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn 46.88%
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn 40.60%
5 Novartis Ag 306.35 Bn 279.93 Bn - -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn 39.77%
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn 46.62%
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn 50.63%
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn 42.49%
10 NextCure 29.30 Mn -71.08 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2020 40.05%
Dec 31, 2019 -560.75%
Sep 30, 2019 -563.11%
Jun 30, 2019 -597.22%
Mar 31, 2019 -460.72%
API Access

NextCure EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=NXTC&period=max&api_key=YOUR_API_KEY